• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Poll results: Preferred treatment plans for mild-stage POAG


See our latest poll results

Optometry Times® polled our audience with the following question from January 28, 2022 to February 11, 2022:​ If diagnosed with mild-stage POAG, what would be your preferred treatment plan?

The poll appeared on optometrytimes.com and was promoted on social media channels. Results show the majority of responding ODs would initiate medical therapy with a topical glaucoma medication.

22 ODs responded, in total. Of these:

  • 15 responded "Initiate medical therapy with a topical glaucoma medication"
  • 4 responded "Have selective laser trabeculoplasty (SLT)"
  • 3 responded "Have a minimally invasive glaucoma surgery (MIGS)"

Check out our latest poll: What is your big goal for 2022?

Related Videos
Lorraine Provencher, MD, presenting slides
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Melissa Tawa, OD, FAAO
Deborah Ristvedt, DO, details CIME 2024 presentation on glaucoma management
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Nate Lighthizer, OD, speaks on lasers in optometry at AAOpt 2023
© 2024 MJH Life Sciences

All rights reserved.